OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time BOERSE MUENCHEN 09:06:45 03/07/2024 pm IST | ||
| 14.95 EUR | -6.91% |
|
| Current month | -0.56% | ||
| 1 month | +11.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 14.95 | -6.91% |
| 02/24/02 | 16.06 | -3.31% |
| 01/24/01 | 16.61 | +2.85% |
| 28/24/28 | 16.15 | -1.58% |
| 27/24/27 | 16.41 | +0.31% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 09:06 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | HG6CYA |
| ISIN | DE000HG6CYA7 |
| Date issued | 17/10/2022 |
| Strike | 56.79 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.63 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.11 € |
|---|---|
| Lowest since issue | 0.24 € |
| Spread | 0.02 € |
| Spread % | 0.13% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
